2026 Pyrotinib Maleate Post-Reimbursement Price Calculation

Pyrotinib Maleate (Pyrotinib Maleate) has been independently developed and marketed in China and has been included in the scope of medical insurance, becoming an affordable targeted treatment option for patients with HER2-positive late-stage breast cancer. The domestic selling price of each box is generally in the range of 2,000 to 4,000 yuan, and the specific price will vary slightly depending on dosage specifications and purchasing channels. After medical insurance reimbursement, the actual amount paid by the patient depends on factors such as local medical insurance policies, personal reimbursement ratios, and annual payment thresholds. Therefore, the out-of-pocket costs of the same drug may differ in different regions.

The introduction of medical insurance coverage not only significantly reduces the financial burden on patients, but also improves the accessibility of targeted treatments. SinceHER2-positive breast cancer is mostly a long-term management disease, the cost of long-term medication used to be an important limiting factor for patients in choosing treatment options. As an oral small molecule tyrosine kinase inhibitor, pyrotinib not only ensures efficacy, but also allows patients to continue receiving treatment through the medical insurance reimbursement system, reducing the risk of discontinuing medication due to financial pressure.

In actual calculations, patients need to first confirm the reimbursement ratio and personal deductible amount in the medical insurance catalog. For example, if the price of each box is RMB 3,500, the medical insurance reimbursement ratio is 70%, and the threshold has been met, the patient will actually pay about 1,050 yuan per box. However, the actual cost will be adjusted based on local medical insurance policies, the patient’s cumulative medication cycles, and reimbursement limits. Hospital pharmacies usually provide detailed reimbursement guides and cost accounting services. Patients can consult their doctors or pharmacists before purchasing medicines in order to reasonably arrange their treatment budget.

It is worth noting that pyrotinib has been proven to have significant efficacy in the second-line treatment of HER2-positive breast cancer. Its affordable price after reimbursement makes it a clinically recommended targeted therapy. In the future, with the further improvement of drug policies and the introduction of generic drugs, patients will have access to more cost-effective treatment options while ensuring treatment continuity and efficacy stability.

Reference materials:https://synapse.patsnap.com/article/what-is-pyrotinib-maleate-used-for